Pfizer’s arrival at patent cliff elicits concern from Congress
Pfizer yesterday became the latest major pharmaceutical manufacturer to see a leading drug patent expire with the introduction of generic versions of Lipitor - and now the company’s strategy for coping with the revenue loss has raised eyebrows in Congress
Many other high-profile drug patents are expected to expire in the next year. "The patent cliff that has been threatening the pharmaceutical industry has finally arrived," said IBISWorld analyst Sophia Snyder.
Pfizer reported $10.7 billion in Lipitor revenues in 2010,...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.